Cargando…

The influence of a polymorphism in the gene encoding angiotensin converting enzyme (ACE) on treatment outcomes in late-onset Pompe patients receiving alglucosidase alfa

Correlations between angiotensin-converting enzyme (ACE) genotype (I/I, I/D, D/D), disease severity at baseline and response to enzyme replacement therapy (ERT) were assessed in the Pompe disease Late-Onset Treatment Study (LOTS). No correlations were observed between ACE genotype and disease severi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baek, Rena C., Palmer, Rachel, Pomponio, Robert J., Lu, Yuefeng, Ma, Xiwen, McVie-Wylie, Alison J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961277/ https://www.ncbi.nlm.nih.gov/pubmed/27489778 http://dx.doi.org/10.1016/j.ymgmr.2016.07.005

Ejemplares similares

Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease
por: Beck, Michael
Publicado: (2009)

Alglucosidase alfa: 5 years of experience in late-onset Pompe disease
por: Schoser, Benedikt
Publicado: (2013)

Long-Term Experience with Anaphylaxis and Desensitization to Alglucosidase Alfa in Pompe Disease
por: Ertoy Karagol, Hacer Ilbilge, et al.
Publicado: (2023)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2017)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
por: Kanters, Tim A, et al.
Publicado: (2014)

A Multi-Centre Prospective Study of the Efficacy and Safety of Alglucosidase Alfa in Chinese Patients With Infantile-Onset Pompe Disease
por: Zhu, Diqi, et al.
Publicado: (2022)

Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long‐term clinical outcome of classic infantile Pompe patients
por: Poelman, Esther, et al.
Publicado: (2020)

Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences
por: Chien, Yin-Hsiu, et al.
Publicado: (2020)

STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa
por: Gutschmidt, Kristina, et al.
Publicado: (2021)

Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions
por: Ditters, Imke A. M., et al.
Publicado: (2023)

Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study
por: van Gelder, C. M., et al.
Publicado: (2016)

Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV
por: Yi, Haiqing, et al.
Publicado: (2016)

Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α
por: Kishnani, Priya, et al.
Publicado: (2017)

Multicenter, non-interventional, double cohort study to assess the safety of alglucosidase alfa and laronidase in real-world home infusion setting
por: Toscano, Antonio, et al.
Publicado: (2022)

Double dose alglucosidase-alpha doubles benefit?
por: Finsterer, Josef, et al.
Publicado: (2018)

Angiotensin Converting Enzyme (ACE) and ACE2 Bind Integrins and ACE2 Regulates Integrin Signalling
por: Clarke, Nicola E., et al.
Publicado: (2012)

Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome
por: Gómez, Juan, et al.
Publicado: (2020)

The angiotensin-converting enzyme (ACE) gene family of Anopheles gambiae
por: Burnham, Susan, et al.
Publicado: (2005)

Angiotensin converting enzyme gene polymorphism and influence of ACE inhibition
por: Arman, Q.
Publicado: (2010)

Manipulating angiotensin metabolism with angiotensin converting enzyme 2 (ACE2) in heart failure
por: Patel, Vaibhav B., et al.
Publicado: (2012)

The Race for ACE: Targeting Angiotensin-Converting Enzymes (ACE) in SARS-CoV-2 Infection
por: Schieffer, Elisabeth, et al.
Publicado: (2022)

Three key proteases – angiotensin-I-converting enzyme (ACE), ACE2 and renin – within and beyond the renin-angiotensin system
por: Guang, Cuie, et al.
Publicado: (2012)

The Insertion/Deletion Polymorphism of the Angiotensin Converting Enzyme (ACE) in Parkinson’s Disease
por: Papapetropoulos, Spiridon, et al.
Publicado: (2008)

Angiotensin-I-Converting Enzyme (ACE)-Inhibitory Peptides from Plants
por: Daskaya-Dikmen, Ceren, et al.
Publicado: (2017)

Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19
por: Ni, Wentao, et al.
Publicado: (2020)

Covid-19 and the angiotensin-converting enzyme (ACE2): Areas for research
por: Omar, Michael Brandon
Publicado: (2020)

Characterization of Angiotensin Converting Enzyme-2 (ACE2) in Human Urine
por: Lew, Rebecca A., et al.
Publicado: (2006)

Angiotensin Converting Enzyme (ACE): A Marker for Personalized Feedback on Dieting
por: Tejpal, Shilpa, et al.
Publicado: (2020)

Purification and characterization of angiotensin-converting enzyme (ACE) from sheep lung
por: Aydin, Fatih, et al.
Publicado: (2021)

Structural determinants for binding to angiotensin converting enzyme 2 (ACE2) and angiotensin receptors 1 and 2
por: Clayton, Daniel, et al.
Publicado: (2015)

Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
por: Fiege, Lina, et al.
Publicado: (2023)

DNA Methylation Analysis of the Angiotensin Converting Enzyme (ACE) Gene in Major Depression
por: Zill, Peter, et al.
Publicado: (2012)

Angiotensin Converting Enzyme (ACE) Inhibitor Extends Caenorhabditis elegans Life Span
por: Kumar, Sandeep, et al.
Publicado: (2016)

Angiotensin-converting enzyme 2 (ACE2) is upregulated in Alzheimer’s disease brain
por: Ding, Qiyue, et al.
Publicado: (2020)

Measurement of Angiotensin Converting Enzyme 2 Activity in Biological Fluid (ACE2)
por: Xiao, Fengxia, et al.
Publicado: (2017)

Angiotensin Converting Enzyme-2 (ACE-2) role in disease and future in research
por: Abdul-Hafez, Amal, et al.
Publicado: (2021)

Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19
por: Kuba, Keiji, et al.
Publicado: (2021)

Identification and characterisation of the angiotensin converting enzyme-3 (ACE3) gene: a novel mammalian homologue of ACE
por: Rella, Monika, et al.
Publicado: (2007)

Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease
por: Tikellis, Chris, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_gu5s8l29e02n531k6um6ut2qcn